

Supplementary

Table S1 This summary outlines the specific clinical characteristics of each cohort

Accession	TCGA-ACC	GSE19750	GSE10927	GSE76019
Platform	Illumina RNAseq	Affymetrix Human Genome U133 Plus 2.0 Array		Affymetrix HT HG-U133+ PM Array Plate
GPL			GPL570	GPL13158
PMID		24238056 26963385	19147773	27307598 32147670
Number of All	79	48	65	34
Number of ACC patients with survival information (%)	79 (100%)	22 (46%)	24 (36%)	34 (100%)
Age, years				Children
≤65	68	5	22	
>65	11	17	2	
Not available	0	0	0	
Gender				
Male	31	11	7	12
Female	48	11	17	22
Stage				
I + II	46	8	13	17
III + IV	31	14	11	17
Not available	2	0	0	0
Survival status				
Alive	51	4	7	26
Dead	28	18	17	8
Overall survival range (median) (months)	10–389 (80.2)	0–216 (37.2)	1–149.6 (19)	
Progression-free survival range (median) (months)	0.9–389 (37.2)			
Event-free survival range (median) (months)				1.9–85 (NA)




Figure S1 Nomogram construction (A) and performance evaluation (B-D). TCGA-ACC (n=79). PFI, progression-free interval; AUC, area under the curve.